Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781894 | 0.84 | MAPK11 (0.46) | MEN1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL9082886 | 0.80 | MEN1 (0.62) | ALDH1A1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL5780807 | 0.78 | MAOB (0.67) | MEN1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL5779949 | 0.75 | MAOB (0.60) | ALDH1A1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL5777726 | 0.75 | MAPT (0.46) | MAPTMAPK14MAPK11 | |
| SCHEMBL5780609 | 0.75 | MAOB (0.54) | MEN1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL5780051 | 0.74 | CCR2 (0.53) | MAPTNPC1RAB9AMAPK14MAPK11 | |
| SCHEMBL5487229 | 0.73 | KMT2A (0.52) | ALDH1A1MEN1MAPTKMT2ARPS6KA2 | |
| SCHEMBL5495459 | 0.73 | GRM4 (0.53) | ALDH1A1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL6179586 | 0.73 | PTGER3 (0.49) | ALDH1A1MEN1MAPTKMT2ARPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383757-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2006-09-27 | — | — | EP | claimed |
| US-20040127513-A1 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. | 2004-07-01 | — | — | US | claimed |
| EP-1383757-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2004-01-28 | — | — | EP | claimed |
| US-20030092728-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-15 | — | — | US | claimed |
| WO-2002081463-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| EP-1383757-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2006-09-27 | — | — | EP | disclosed |
| US-6998407-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1383757-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-6677365-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; RHEUMATIC DISEASES; CARDIOVASCULAR DISORDERS | TELIK, INC. | 2004-01-13 | — | — | US | disclosed |
| WO-2002081463-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092728-A1 | Antagonists of MCP-1 function and methods of use thereof | CCL11, CCR1, CCR2 | ALDH1A1 2205/4885MEN1 2213/4885MAPT 2071/4885 |
| US-20040127513-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | ALDH1A1 2420/4885MEN1 1988/4885MAPT 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.